Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Zura Bio Limited Class A Ordinary Shares (ZURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/26/2025: ZURA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -65.39% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/26/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 88.47M USD | Price to earnings Ratio - | 1Y Target Price 13.86 |
Price to earnings Ratio - | 1Y Target Price 13.86 | ||
Volume (30-day avg) 262722 | Beta 0.06 | 52 Weeks Range 1.07 - 6.35 | Updated Date 03/27/2025 |
52 Weeks Range 1.07 - 6.35 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.61 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.61% | Return on Equity (TTM) -43.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 87508672 | Price to Sales(TTM) - |
Enterprise Value 87508672 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.34 | Shares Outstanding 65293500 | Shares Floating 42152503 |
Shares Outstanding 65293500 | Shares Floating 42152503 | ||
Percent Insiders 30.43 | Percent Institutions 59.96 |
Analyst Ratings
Rating 4.62 | Target Price 15 | Buy 1 | Strong Buy 6 |
Buy 1 | Strong Buy 6 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zura Bio Limited Class A Ordinary Shares
Company Overview
History and Background
Zura Bio Limited is a clinical-stage biotechnology company focused on developing novel medicines for immunological diseases. Founded with the goal of addressing unmet needs in this therapeutic area, Zura Bio has grown through strategic acquisitions and internal development programs.
Core Business Areas
- Immunology Drug Development: Focuses on researching, developing, and commercializing therapies for immunological disorders, including chronic inflammatory diseases and autoimmune conditions.
Leadership and Structure
The leadership team comprises experienced pharmaceutical executives and scientific advisors. The organizational structure is based on functional departments (R&D, clinical development, commercialization) reporting to the CEO.
Top Products and Market Share
Key Offerings
- Tibetanoximod: A Phase 2 ready molecule for Systemic Sclerosis and NASH. The market is competitive with players like Bristol Myers Squibb and Boehringer Ingelheim.
Market Dynamics
Industry Overview
The immunology market is experiencing significant growth driven by an aging population, increased prevalence of autoimmune diseases, and advancements in biopharmaceutical research. There is high competition and high regulatory hurdles.
Positioning
Zura Bio positions itself as an innovator in the immunology space, focusing on novel targets and pathways. Competitive advantages include intellectual property and clinical expertise.
Total Addressable Market (TAM)
The global immunology market is estimated at $150 billion. Zura Bio aims to capture a portion of this market through the successful development and commercialization of its product candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates
- Experienced management team
- Strong intellectual property position
- Clinical-stage pipeline
Weaknesses
- Limited financial resources
- High dependence on clinical trial outcomes
- Lack of commercial infrastructure
- Early stage company
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- FDA fast track designation
- Advancements in immunotherapy
Threats
- Clinical trial failures
- Competition from established players
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- BMY
- LLY
- ABBV
- GILD
- MRK
Competitive Landscape
Zura Bio faces intense competition from larger, more established pharmaceutical companies. Its advantage lies in its novel therapeutic approach. Disadvantages include limited resources compared to big pharma.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is primarily driven by advancement of pipeline programs.
Future Projections: Future growth depends on successful clinical trials and potential partnerships.
Recent Initiatives: Recent initiatives include advancing Tibetanoximod into Phase 2 trials.
Summary
Zura Bio is a clinical-stage company with a promising pipeline. Successful clinical trials are necessary for sustained growth. The company is dependent on funding and partnerships. Competition from established players is a significant risk. Overall, it is a high-risk, high-reward biotech company with potential in the immunology space.
Similar Companies
- VIR
- VRNA
- CRSP
- MRTX
- AGEN
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Data is based on available information and may be subject to change. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zura Bio Limited Class A Ordinary Shares
Exchange NASDAQ | Headquaters Henderson, NV, United States | ||
IPO Launch date 2021-09-03 | CEO & Director Mr. Robert Lisicki | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://zurabio.com |
Full time employees 30 | Website https://zurabio.com | ||
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.